Clinical trials: Medium Vessel Occlusion
Acute Ischemic Stroke, Endovascular Thrombectomy
Evaluation of Endovascular Treatment in Acute Intracranial Distal Medium Vessel Occlusion Stroke
Rationale: Distal Medium Vessel Occlusion (MeVO) are thought to cause as many as 25% to 40% of all acute ischemic strokes (AIS).
- Trial name
- NCT06146790
- Testing
- endovascular treatment, Standard medical management
- Where
- China
- Volunteers
- 564 people
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
Acute Ischemic Stroke
Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours of Onset With Prourokinase
Ischemic cerebrovascular disease is a common neurological disorder with high incidence, mortality, and disability. Early reperfusion to salvage the ischemic penumbra is the cornerstone of acute ischemic stroke (AIS) treatment.
- Trial name
- NCT07550296
- Testing
- prourokinase
- Where
- China
- Volunteers
- 122 people
- Sponsor
- General Hospital of Shenyang Military Region
Acute Ischemic Stroke, Medium Vessel Occlusion
Intra-arterial Recombinant Human Tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA) Thrombolysis for Acute Medium Vessel Occlusion
Medium vessel occlusion (MeVO) accounts for 20-45% of acute ischemic stroke (AIS). Although patients with MeVO often present with relatively low NIHSS scores, up to one-third remain functionally dependent at follow-up despite…
- Trial name
- MeVO-TNK Ⅱ (NCT07302854)
- Testing
- Intra-arterial Thrombolysis, Standard medical treatment
- Where
- China
- Volunteers
- 382 people
- Sponsor
- Xiang Luo
Coronary Artery Disease, Coronary Stenosis
Contrast Enhancement on Coronary Computed Tomographic Angiography
Computed tomographic angiography (CTA) is an important prognostic tool with regard to the detection of coronary artery stenoses.
- Trial name
- EICAR (NCT02462044)
- Testing
- 240 mg Iodine, 300 mg Iodine, 370 mg Iodine
- Where
- Netherlands
- Volunteers
- 200 people
- Sponsor
- Maastricht University Medical Center
Hyperthyroidism, Graves Disease
Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis
During July 2019 to August 2020, a single-blind clinical trial was done to 36 patients with Graves' disease. At the beginning of the study, subjects were accommodated into 2 groups, 17 into PTU groups and 19 into methimazole…
- Conditions
- Hyperthyroidism, Graves Disease, Atherosclerosis of Artery, Pathophysiology
- Trial name
- NCT05118542
- Testing
- Propylthiouracil, Methimazole
- Where
- Indonesia
- Volunteers
- 36 people
- Sponsor
- Universitas Indonesia